Macrogenics Inc (NASDAQ: MGNX)’s stock price has soared by 10.32 in relation to previous closing price of 1.26. Nevertheless, the company has seen a gain of 7.75% in its stock price over the last five trading days. zacks.com reported 2025-04-17 that The U.S. government’s tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Is It Worth Investing in Macrogenics Inc (NASDAQ: MGNX) Right Now?
Additionally, the 36-month beta value for MGNX is 2.18. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for MGNX is 58.00M and currently, short sellers hold a 9.69% ratio of that float. The average trading volume of MGNX on April 22, 2025 was 778.08K shares.
MGNX’s Market Performance
MGNX’s stock has seen a 7.75% increase for the week, with a -33.81% drop in the past month and a -53.67% fall in the past quarter. The volatility ratio for the week is 14.51%, and the volatility levels for the past 30 days are at 12.55% for Macrogenics Inc The simple moving average for the past 20 days is 5.54% for MGNX’s stock, with a -56.91% simple moving average for the past 200 days.
MGNX Trading at -29.62% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.62% of loss for the given period.
Volatility was left at 12.55%, however, over the last 30 days, the volatility rate increased by 14.51%, as shares sank -30.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.82% lower at present.
During the last 5 trading sessions, MGNX rose by +7.75%, which changed the moving average for the period of 200-days by -66.10% in comparison to the 20-day moving average, which settled at $1.3170. In addition, Macrogenics Inc saw -57.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Smith Beth Ann, who sale 423 shares at the price of $2.56 back on Feb 15 ’25. After this action, Smith Beth Ann now owns 9,532 shares of Macrogenics Inc, valued at $1,083 using the latest closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -0.75 for the present operating margin
- 0.89 for the gross margin
The net margin for Macrogenics Inc stands at -0.45. The total capital return value is set at -0.54. Equity return is now at value -49.85, with -23.20 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -1.83. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is -99.17.
Currently, EBITDA for the company is -57.37 million with net debt to EBITDA at 2.53. When we switch over and look at the enterprise to sales, we see a ratio of -0.39. The receivables turnover for the company is 34.43for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.92.
Conclusion
In conclusion, Macrogenics Inc (MGNX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
